摘要
目的:比较哌罗匹隆与阿立哌唑治疗精神分裂症的疗效和安全性。方法:选择符合CCMD-3诊断的精神分裂症患者80例,随机分为两组,分别使用哌罗匹隆与阿立哌唑口服治疗,观察8周。以阳性与阴性症状量表(PANSS)减分率评定疗效,用治疗中出现的症状量表(TESS)评定不良反应。结果:治疗结束时,哌罗匹隆组与阿立哌唑组在有效率、PANSS评分和不良反应两组比较差异无统计学意义(P>0.05)。结论:哌罗匹隆与阿立哌唑治疗精神分裂症疗效均好,不良反应轻。
Objective：To compare the efficacy and safety of Perospirone and Aripiprazole in the treatment of Schizophrenia. Methods：80 patients with schizophrenia by CC MD -3 were randomly into two groups treated with Perospirone or Aripiprazole for 8 weeks . The ratio of the reduction of Positive and Negative Symptom Scale （PANSS） was used to assess efficacy , and the treatment e- mergent symptom scale （TESS） was used to assess side effects. Results： In the end of curing ,the two groups showed no statistical difference in the efficacy rate, the scores of PANSS, and the adverse effect （ P 〉 0.05 ） . Conclusions ： Both Perospirone and Aripiprazole are effective and few adverse effect for patients with schizophrenia.
出处
《中国民康医学》
2012年第17期2053-2054,共2页
Medical Journal of Chinese People’s Health
